As PTP1B is a negative regulator of the ISP, PTP1B inhibitors have been considered novel and potential target drugs for the recovery from obesity and T2DM [32, 33]. This evidence concerns the gene PTPN1 and obesity due to melanocortin 4 receptor deficiency.